{"brief_title": "Study Evaluating ReFacto\u00ae in Hemophilia A Undergoing Major Surgery", "brief_summary": "The primary objective of this clinical research study is to evaluate the safety and efficacy of ReFacto in subjects with hemophilia A undergoing major surgery monitored using the chromogenic substrate assay at the local laboratory.", "condition": ["Hemophilia A"], "intervention_type": ["Drug"], "intervention_name": ["ReFacto"], "criteria": "Inclusion Criteria: - Age \u2265 6 years - Male previously treated patients (\u2265150 Exposure Days) with moderate or severe hemophilia A (i.e. \u2264 5% FVIII:C) who will undergo elective major surgery that is anticipated to require at least 6 consecutive days of daily factor VIII (FVIII) infusions (surgical and post-surgical prophylaxis) - Ability to adhere to the protocol requirements Exclusion Criteria: - Hypersensitivity to ReFacto, murine allergen, or hamster allergen 2 History of FVIII inhibitor or current inhibitor, defined as > 0.6 BU - Prior participation in this study - Any concomitant bleeding disorder other than hemophilia A", "gender": "Male", "minimum_age": "6 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Hemophilia A", "mesh_term": ["Hemophilia A", "Factor VIII"], "id": "NCT00092976"}